Latest MVA85A Stories
Canadian researchers have developed a new tuberculosis vaccine that could boost or perhaps replace the only existing way to immunize against the infection.
A new vaccine considered to be the most advanced for tuberculosis among more than a dozen now in trials has failed its study. Researchers said they were disappointed by the results of the study, which showed that the vaccine offered little to no protection at all from TB.
New, more effective vaccines will be decisive in the fight against TB. More than 10 million children have been orphaned by the disease, which is rapidly becoming resistant to available treatment options.
The University of Oxford and Emergent BioSolutions have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium, to further develop MVA85A, a clinically advanced vaccine candidate for the prevention of tuberculosis.
The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) announced today that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd.
By Patricia Reaney LONDON (Reuters) - Tuberculosis vaccines being tested in developed countries will not protect people living in parts of the developing world where they are most needed because they trigger a different body response, researchers said on Monday.